Biotech: Xaira Therapeutics raises $1 billion in funding – By Nuadox Crew – U.S.-based Xaira Therapeutics, a newly launched biotechnology company, aims to revolutionize the drug discovery and development process by leveraging advanced AI technologies. Co-founded by ARCH Venture Partners, Foresite Labs, and Dr. David Baker of UW Medicine, Xaira launches with over $1 billion in funding. Led by Dr. Marc Tessier-Lavigne, former Genentech CSO, the company integrates AI research, expansive data generation, and therapeutic product development to accelerate the delivery of effective therapies. – Source: Xaira Therapeutics Read Also Read Also This AI model directly compares the properties of prospective new pharmaceuticals
This content was originally published here.
